Given that γδ T cells are unlikely to cause graft-versus-host disease (GVHD) because their TCR ligands (IPP, MICA, etc.)are not MHC-restricted, γδ T cells (with or without genetic modification) could be generated from healthy donors in a third party manufacturing facility and given in the allogeneic setting as an “off-the-shelf” therapeutic. This evidence concerns the gene IPP and graft versus host disease.